TP53 and non-small cell lung carcinoma: In the datasets other than the POPLAR/OAK cohort, we analyzed the PFS on ICIs of the nonsquamous NSCLC patients with TP53/KRASG12C co-mutation, which was relatively longer than the ones without co-mutation (P = 0.067, Supplementary Fig. 12B).